Literature DB >> 31757304

Intravesical Gene Therapy.

Vikram M Narayan1, Colin P N Dinney2.   

Abstract

Non-muscle-invasive bladder cancer is a challenging disease to treat, with few effective salvage intravesical options available for patients who develop bacillus Calmette-Guerin-unresponsive disease. Although radical cystectomy with pelvic lymphadenectomy remains the gold standard treatment for these patients, there remains an unmet need for other options for those who are unable or unwilling to undergo surgery. To this end, intravesical gene therapy is emerging as a potential alternative with promising early data and ongoing efforts to better understand the mechanisms of action to optimize therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BCG-unresponsive; Bladder cancer; Immunogene therapy; Interferon-alpha; Intravesical gene therapy

Mesh:

Year:  2020        PMID: 31757304      PMCID: PMC6986363          DOI: 10.1016/j.ucl.2019.09.011

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  49 in total

1.  Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

Authors:  Silvia Hernández; Elena López-Knowles; Josep Lloreta; Manolis Kogevinas; Alex Amorós; Adonina Tardón; Alfredo Carrato; Consol Serra; Núria Malats; Francisco X Real
Journal:  J Clin Oncol       Date:  2006-08-01       Impact factor: 44.544

2.  Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.

Authors:  Carolyn D Hurst; Olivia Alder; Fiona M Platt; Alastair Droop; Lucy F Stead; Julie E Burns; George J Burghel; Sunjay Jain; Leszek J Klimczak; Helen Lindsay; Jo-An Roulson; Claire F Taylor; Helene Thygesen; Angus J Cameron; Anne J Ridley; Helen R Mott; Dmitry A Gordenin; Margaret A Knowles
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743

3.  Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens.

Authors:  Robert J Connor; Jennifer M Anderson; Todd Machemer; Daniel C Maneval; Heidrun Engler
Journal:  Urology       Date:  2005-07       Impact factor: 2.649

4.  An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.

Authors:  Vignesh T Packiam; Donald L Lamm; Daniel A Barocas; Andrew Trainer; Benjamin Fand; Ronald L Davis; William Clark; Michael Kroeger; Igor Dumbadze; Karim Chamie; A Karim Kader; Dominic Curran; John Gutheil; Arthur Kuan; Alex W Yeung; Gary D Steinberg
Journal:  Urol Oncol       Date:  2017-07-26       Impact factor: 3.498

5.  Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers.

Authors:  C M Iqbal Ahmed; D E Johnson; G W Demers; H Engler; J A Howe; K N Wills; S F Wen; J Shinoda; J Beltran; M Nodelman; T Machemer; D C Maneval; T L Nagabhushan; B J Sugarman
Journal:  Cancer Gene Ther       Date:  2001-10       Impact factor: 5.987

Review 6.  Long-term results of intravesical therapy for superficial bladder cancer.

Authors:  D L Lamm
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

Review 7.  The basic science of gene therapy.

Authors:  R C Mulligan
Journal:  Science       Date:  1993-05-14       Impact factor: 47.728

8.  A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.

Authors:  James M Burke; Donald L Lamm; Maxwell V Meng; John J Nemunaitis; Joseph J Stephenson; James C Arseneau; Junko Aimi; Seth Lerner; Alex W Yeung; Troy Kazarian; Daniel J Maslyar; James M McKiernan
Journal:  J Urol       Date:  2012-10-22       Impact factor: 7.450

9.  Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.

Authors:  Lance C Pagliaro; Afsaneh Keyhani; Dallas Williams; Denise Woods; Baoshun Liu; Paul Perrotte; Joel W Slaton; James A Merritt; H Barton Grossman; Colin P Dinney
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

Review 10.  Immunotherapy for bladder cancer.

Authors:  Oliver Fuge; Nikhil Vasdev; Paula Allchorne; James Sa Green
Journal:  Res Rep Urol       Date:  2015-05-04
View more
  1 in total

Review 1.  Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning.

Authors:  Kelly Ward; Mark O Kitchen; Suresh-Jay Mathias; Farhat L Khanim; Richard T Bryan
Journal:  Front Surg       Date:  2022-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.